Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2009-01-09
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 433
- Registration Number
- NCT00819741
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Shanghai, China
Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- InflammationRheumatoid ArthritisHealthy
- Interventions
- Drug: placebo
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT00818064
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 44
- Registration Number
- NCT00813020
Observational Study to Investigate the Efficacy and Safety of Human Insulin or Insulin Analogue Treatments in Type 2 Diabetes Subjects
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: insulin analogue
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4847
- Registration Number
- NCT00806936
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir®
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 74
- Registration Number
- NCT00806897
- Locations
- 🇱🇹
Novo Nordisk Investigational Site, Vilnius, Lithuania
Observational Study of NovoPen® 4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus
Completed
- Conditions
- Diabetes Mellitus, Type 2Delivery SystemsDiabetesDiabetes Mellitus, Type 1
- Interventions
- Device: NovoPen® 4
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 526
- Registration Number
- NCT00806858
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
Comparing the Efficacy and Safety of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 on Blood Sugar Control in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 145
- Registration Number
- NCT00807092
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Thailand
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
- Interventions
- Other: No treatment given
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2342
- Registration Number
- NCT00805922
- Locations
- 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand
Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes
Phase 4
Terminated
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2008-11-27
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT00799448
- Locations
- 🇬🇷
Novo Nordisk Investigational Site, Athens, Greece
Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT00795600
© Copyright 2025. All Rights Reserved by MedPath